Nyxoah SA (EBR:NYXH)
Belgium · Delayed Price · Currency is EUR | Market Cap | 105.66M -45.4% |
| Revenue (ttm) | 15.33M +251.2% |
| Net Income | -83.65M |
| EPS | -2.11 |
| Shares Out | 43.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 144,423 |
| Average Volume | 91,296 |
| Open | 2.460 |
| Previous Close | 2.485 |
| Day's Range | 2.370 - 2.535 |
| 52-Week Range | 2.350 - 8.870 |
| Beta | 0.88 |
| RSI | 41.28 |
| Earnings Date | May 12, 2026 |
About Nyxoah
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. [Read more]
Financial Performance
In 2025, Nyxoah's revenue was 10.02 million, an increase of 121.63% compared to the previous year's 4.52 million. Losses were -90.09 million, 52.1% more than in 2024.
Financial StatementsNews
Information on the total number of voting rights and shares
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), May 20, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2...
Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum
Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum
Nyxoah Transcript: Bank of America Global Healthcare Conference 2026
A differentiated neuromodulation solution for obstructive sleep apnea is gaining rapid U.S. adoption, with strong clinical outcomes and robust financial growth. Expansion in Europe shows swift market share gains, and future plans focus on innovation and AI-driven care.
Nyxoah Transcript: Bank of America Global Healthcare Conference 2026
A differentiated neuromodulation solution for obstructive sleep apnea is gaining rapid U.S. adoption, with strong clinical outcomes and robust financial growth. Expansion in Europe shows swift market share gains, and future plans focus on innovation and AI-driven care.
Nyxoah price target lowered to $7 from $9 at Piper Sandler
Piper Sandler lowered the firm’s price target on Nyxoah (NYXH) to $7 from $9 and keeps an Overweight rating on the shares following quarterly results. Genio launch appears to be…
Nyxoah Q1 Earnings Call Highlights
Nyxoah NASDAQ: NYXH reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the compan...
Nyxoah reports Q1 EPS (EUR 0.37) vs. (EUR 0.60) last year
Reports Q1 revenue EUR 6.37M vs. EUR 1.06M last year. “Our first quarter revenue results reflect strong execution of our U.S. launch. The 25% sequential quarterly revenue growth was driven…
Nyxoah Earnings Call Transcript: Q1 2026
Q1 2026 saw 13% sequential worldwide revenue growth, led by a 25% U.S. increase and strong account activation. Gross margin was impacted by production issues but is expected to recover, with full-year revenue guidance set at EUR 36-40 million and stable reimbursement outlook.
Nyxoah Earnings Call Transcript: Q1 2026
Q1 2026 saw 13% sequential worldwide revenue growth, led by a 25% U.S. increase and strong account activation. Gross margin was impacted by production issues but is expected to recover, with full-year revenue guidance set at EUR 36-40 million and stable reimbursement outlook.
Nyxoah Earnings release: Q1 2026
Nyxoah released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Nyxoah Earnings Call Transcript: Q1 2026
Q1 2026 saw 13% sequential worldwide revenue growth, led by a 25% U.S. increase and strong account activation. Gross margin was impacted by production issues but is expected to recover, with full-year revenue guidance set at EUR 36-40 million and stable reimbursement outlook.
Nyxoah Earnings release: Q1 2026
Nyxoah released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Nyxoah Reports First Quarter 2026 Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports First Quarter 2026 Financial and Operating Results Strong Genio launch in the U.S. drove 25% sequential quarterly U.S. revenue growth Continued clarity around HGNS...
Nyxoah downgraded to Hold from Buy at Stifel
Stifel downgraded Nyxoah (NYXH) to Hold from Buy with a price target of $5, down from $8. The downgrade is not specific to the Q1 earnings announcement due tomorrow after…
Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026
Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026 Mont-Saint-Guibert, Belgium – April 28, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or t...
Nyxoah price target lowered to $8 from $10 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on Nyxoah (NYXH) to $8 from $10 and keeps a Buy rating on the shares. The firm’s checks suggest the Q1
Nyxoah price target lowered to $4.62 from $5.87 at Baird
Baird analyst David Rescott lowered the firm’s price target on Nyxoah (NYXH) to $4.62 from $5.87 and keeps a Neutral rating on the shares. The firm updatedits mdel as its
Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), March 20, 2026 , 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 20...
Nyxoah price target lowered to $10 from $11 at Stifel
Stifel lowered the firm’s price target on Nyxoah (NYXH) to $10 from $11 and keeps a Buy rating on the shares. The firm, which updated its model for “some moving
Nyxoah Earnings Call Transcript: Q4 2025
2025 saw transformative growth with FDA approval and U.S. launch, driving 122% revenue growth and strong Q4 results. U.S. net revenue is expected to grow 25% sequentially in early 2026, with expanding sales coverage and improving gross margins.
Nyxoah Earnings Call Transcript: Q4 2025
2025 saw transformative growth with FDA approval and U.S. launch, driving 122% revenue growth and strong Q4 results. U.S. net revenue is expected to grow 25% sequentially in early 2026, with expanding sales coverage and improving gross margins.
Nyxoah Annual report: Q4 2025
Nyxoah has published its Q4 2025 annual report on March 19, 2026.
Nyxoah Annual report: Q4 2025
Nyxoah has published its Q4 2025 annual report on March 19, 2026.
Nyxoah Earnings release: Q4 2025
Nyxoah released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Nyxoah Earnings Call Transcript: Q4 2025
2025 saw transformative growth with FDA approval and U.S. launch, driving 122% revenue growth and strong Q4 results. U.S. net revenue is expected to grow 25% sequentially in early 2026, with expanding sales coverage and improving gross margins.